| Name | Title | Contact Details |
|---|
We are a precision medicines company looking to eliminate the “all comer” approach that is seen with today`s treatments for people with autoimmune disease. We are leveraging a precision analytics platform, powered by Foresite Labs, coupled with a team of experts with deep experience in precision medicine drug development and immunology, in order to create medicines that change the lives of people with autoimmune disease.
CRISPR Therapeutics is a leading gene-editing company focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. Our multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Our lead programs in beta-thalassemia and sickle cell disease have advanced to IND/CTA-enabling studies with a CTA filing planned by the end of 2017, and we are advancing additional programs in ex vivo and in vivo disease areas. In addition to our fully-owned programs, our strategic collaborations with Bayer AG and Vertex Pharmaceuticals expand our portfolio and enable us with unique capabilities. Through our private financings, partnerships, and IPO we have raised >$400M to fund and accelerate our portfolio. We have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from our scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. Our company is headquartered in Zug, Switzerland with R&D operations in Cambridge, Massachusetts, USA and some business operations in London, United Kingdom.
San Diego-based Biocept, Inc. (Nasdaq: BIOC) develops and performs diagnostic assays that provide clinically actionable information to improve outcomes for patients with a variety of cancers. Biocept`s unique combination of cell-based and cell-free DNA analysis allows us to rapidly detect and monitor certain cancer biomarkers in blood and cerebrospinal fluid (CSF). Our patented Target Selector™ technology quantitatively analyzes tumor cells for tumor-associated biomarkers, offering high sensitivity and specificity compared with methods currently used by other laboratories. In addition to our broad portfolio of blood-based liquid biopsy tests, we offer the CNSide™ CSF assay, which addresses an unmet clinical need for patients with cancer that has metastasized to the central nervous system. Between 10% and 30% of patients with cancer will develop brain or spinal cord metastasis. Survival is often low, and few are diagnosed early enough for effective therapeutic intervention. CNSide answers three key questions: Is there a tumor? Is there a target for treatment? Is there a trend in treatment response? We offer diagnostic laboratory services for oncologists, pathologists, hospitals, cancer centers, universities, pharmaceutical and clinical researchers, and other healthcare providers. Our CLIA-certified and CAP-accredited laboratory combines a highly trained professional staff with innovative instrumentation for optimal test results and quality control. Biocept works with strategic industry leaders, as well as major cancer centers across the U.S., to further its mission of helping to improve outcomes for cancer patients. We also are utilizing our molecular diagnostic capabilities to offer nationwide RT-PCR-based COVID-19 testing and services to support public health efforts. Revenue from COVID-19 testing has supported further investment in our core oncology business, positioning the company for long-term success.
SAIC-Frederick is a Frederick, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
TriNetX is the global health research network enabling healthcare organizations, biopharmaceutical companies and contract research organizations (CROs) to collaborate, enhance trial design, accelerate recruitment and bring new therapies to market faster. TriNetX combines EMR data such as demographics, diagnoses, procedures, medications, labs, genomics, and deep oncology data with data derived from clinical documentation including discharge summaries, radiology reports, pathology reports, and others, to deliver the industry`s most comprehensive data set for protocol design, feasibility, site selection and patient identification.